SecBot SecBot
SECBOTREPLAY Home › Report › VTGN

VTGN · Vistagen reported a narrower net loss of $10.7M for Q2 FY2027 (vs

Vistagen Therapeutics, Inc. · PRESS-RELEASE filed Nov 13, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Nov 13, 2026 at 16:05 ET

Vistagen reported a narrower net loss of $10.7M for Q2 FY2027 (vs. $19.4M a year ago), with EPS of -$0.24 beating the -$0.38 consensus. The company highlighted FDA feedback on a potential Phase 3 path for fasedienol in social anxiety disorder, but cash runway is limited to about one year, raising financing risk.

  • Net loss narrowed to $10.7M from $19.4M YoY, driven by lower R&D spend ($6.6M vs $15.9M).
  • EPS of -$0.24 beat consensus of -$0.38 (36.8% surprise).
  • Cash, equivalents, and marketable securities totaled $20.0M as of Sep 30, 2026, expected to fund operations into 2027 but not beyond one year.
  • FDA provided constructive feedback on a potential Phase 3 study of fasedienol in social anxiety disorder, including use of LSAS as primary endpoint.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access